Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetrotide Regimens in PCOS Women Undergoing ART
NCT01185704Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2008
- Primary completion
- Oct 2011
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetrorelix in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Merck KGaA. Primary endpoint: Estradiol (E2) Levels on r-hCG Day. Started Nov 2008; status: completed.
02
Drugs
cetrorelix
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT01185704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01185704.